Free 15% Customization On All Syndicated Reports.

Global Molecular Weight Marker Market – North America is expected to account for higher market share of more than 50% driven by presence of many large research laboratories and biotechnology firms such as CELGENE CORP. and Amgen Inc.: Global Market Analysis 2013 – 2017 and Forecast 2018 – 2024

Market Scenario

Global Molecular Weight MarkerMarket is expected to grow at a CAGR of 11% to reach US$ 876.3 million in 2024. The growth is coupled with the increased popularity of personalized medicines for the treatment of chronic diseases and genetic disorders. Personalized medicines involve the application of molecular weight markers for the study of individual’s genome, genes, and diseases. Thus, growing adoption of personalized medicines along with the escalating focus on molecular biology research is expected to boost the demand for molecular weight marker products. Technological advancement in molecular biology products, such as PCR and NGS along with high-quality molecular weight Global Molecular Weight Marker is another major factor contributing towards growth. The recent advancement in these products enables provision of a clearer background and sharp bands. Thus, the demand for molecular weight marker products is expected upsurge soon, which is expected to boost growth. North America dominated the molecular weight markers industry with the largest revenue share, owing to the presence of many large research laboratories and biotechnology firms such as CELGENE CORP. and Amgen Inc. In addition, the highly developed healthcare and research infrastructure in this region have fuelled the Global Molecular Weight Marker growth. Asia Pacific is estimated to exhibit the highest CAGR during the forecast period, owing to rising focus of CROs and biotechnology companies in this region for drug discovery and development. The CROs are focusing on Asian countries such as China and India for clinical trials owing to less stringent government regulations and availability of skilled professionals. These are some of the factors projected to boost the regional Global Molecular Weight Marker growth. Prestained markers were the highest revenue-generating segment in 2017, due to the large application of this product for genomics and proteomics research. Other factors include ability to provide more accurate molecular weight determinations of the sample over a wide molecular weight range. Thus, the popularity of this product is increasing, which is expected to propel the growth of the Global Molecular Weight Marker. Global Molecular Weight Marker

Global Molecular Weight Marker Segmentation

• Global Molecular Weight Marker Market, By Products

o DNA markers  Below 50 bp  50 bp to 100 bp  100 bp to 1 kb  1 kb to 5 kb  Above 5 kb o Protein markers  Below 10 kDa  10 k Da to 100 kDa  100 k Da to 200 kDa  Above 200 kDa o RNA Markers

• Global Molecular Weight Marker Market, By Type

o Prestained markers o Unstained markers o Specialty markers

•Global Molecular Weight Marker Market,  By Applications

o Nucleic acid applications  PCR  Sequencing  Northern blotting  Southern blotting  Molecular cloning  Others o Proteomics applications  Western blotting  Gel extraction  Others

•Global Molecular Weight Marker Market,  By End-Use

o Academic and research institutes o Pharmaceutical and biotechnology companies o CRO's o Others The above data will be provided for following regions/countries from 2013-2024 (USD Million) • North America o U.S. o Canada • Europe o Germany o UK o France o Spain o Italy • Asia Pacific o China o India o Japan o Australia • Latin America o Argentina o Brazil o Mexico • Middle East and Africa o South Africa o Saudi Arabia What information is covered in report? • Actual market numbers from 2013-2017, estimates and forecasts from 2018 to 2024 •  Detailed market segmentation and market share analysis of each segment • Impact analysis of various drivers and trends • Market segmentation and landscape • Competitive landscape, 2017 Global Cold Pain Therapy Market 

Table of Contents

Global Molecular Weight Marker Market

Chapter 1 Research Methodology 1.1. Research Methodology 1.2. Market definition 1.3. Assumptions and Acronyms Used 1.4. Data Sources 1.4.1. Secondary 1.4.1.1. Paid 1.4.1.2. Unpaid 1.4.2. Primary Chapter 2 Executive Summary 2.1. Global Molecular Weight Marker Market overview 2.1.1. By Products 2.1.2. By Type 2.1.3. By Applications 2.1.4. By End-Use Chapter 3 Global Molecular Weight Marker Market Industry Insights 3.1. Market segmentation and scope of study 3.2. Market Drivers and their impact analysis 3.2.1. Market Drivers 3.2.1.1. Increased demand for personalized medicines for the treatment of chronic diseases 3.3. Market share analysis 3.3.1. By Products 3.3.2. By Type 3.3.3. By Applications 3.3.4. By End-Use 3.4. Competitive analysis 3.4.1. Key strategic initiatives 3.4.2. Regional presence 3.4.3. Product overview 3.5. Porter’s analysis 3.6. PESTEL analysis Chapter 4 Molecular Weight Marker Market, By Type 4.1. Key segment trends 4.2. Prestained markers 4.2.1. Market size, by region, 2013 - 2024 4.3. Unstained markers 4.3.1. Market size, by region, 2013 – 2024 4.4. Specialty markers 4.1. Market size, by region, 2013 – 2024 Chapter 5 Molecular Weight Marker Market, By Products 5.1. Key segment trends 5.2. DNA markers 5.2.1. Market size, by region, 2013 - 2024 5.3. Below 50 bp 5.3.1. Market size, by region, 2013 – 2024 5.4. 50 bp to 100 bp 5.4.1. Market size, by region, 2013 – 2024 5.5. 100 bp to 1 kb 5.5.1. Market size, by region, 2013 - 2024 5.6. 1 kb to 5 kb 5.6.1. Market size, by region, 2013 – 2024 5.7. Above 5 kb 5.7.1. Market size, by region, 2013 – 2024 5.8. Protein markers 5.8.1. Market size, by region, 2013 – 2024 5.9. Below 10 kDa 5.9.1. Market size, by region, 2013 – 2024 5.10. 10 k Da to 100 kDa 5.10.1. Market size, by region, 2013 – 2024 5.11. 100 k Da to 200 kDa 5.11.1. Market size, by region, 2013 – 2024 5.12. Above 200 kDa 5.12.1. Market size, by region, 2013 – 2024 5.13. RNA markers 5.13.1. Market size, by region, 2013 – 2024 Chapter 6 Molecular Weight Marker Market, By Applications 6.1. Key segment trends 6.2. Nucleic acid applications 6.2.1. Market size, by region, 2013 - 2024 6.3. PCR 6.3.1. Market size, by region, 2013 – 2024 6.4. Sequencing 6.4.1. Market size, by region, 2013 – 2024 6.5. Northern blotting 6.5.1. Market size, by region, 2013 – 2024 6.6. Southern blotting 6.6.1. Market size, by region, 2013 – 2024 6.7. Molecular cloning 6.7.1. Market size, by region, 2013 – 2024 6.8. Others 6.8.1. Market size, by region, 2013 – 2024 6.9. Proteomics applications 6.9.1. Market size, by region, 2013 – 2024 6.10. Western blotting 6.10.1. Market size, by region, 2013 – 2024 6.11. Gel extraction 6.11.1. Market size, by region, 2013 – 2024 6.12. Others 6.12.1. Market size, by region, 2013 – 2024 Chapter 7 Molecular Weight Marker Market, By Applications 7.1. Key segment trends 7.2. Academic and research institutes 7.2.1. Market size, by region, 2013 - 2024 7.3. Pharmaceutical and biotechnology companies 7.3.1. Market size, by region, 2013 – 2024 7.4. CRO's 7.4.1. Market size, by region, 2013 – 2024 7.5. Others 7.5.1. Market size, by region, 2013 – 2024 Chapter 8 Molecular Weight Marker Market, By Region 8.1. Key regional trends 8.2. North America 8.2.1. Market size, by country, 2013 – 2024 8.2.2. Market size, by products, 2013 – 2024 8.2.3. Market size, by type, 2013 – 2024 8.2.4. Market size, by applications, 2013 – 2024 8.2.5. Market size, by end-use, 2013 – 2024 8.2.6. U.S. 8.2.6.1. Market size, by products, 2013 – 2024 8.2.6.2. Market size, by type, 2013 – 2024 8.2.6.3. Market size, by applications, 2013 – 2024 8.2.6.4. Market size, by end-use, 2013 – 2024 8.2.7. Canada 8.2.7.1. Market size, by products, 2013 – 2024 8.2.7.2. Market size, by type, 2013 – 2024 8.2.7.3. Market size, by applications, 2013 – 2024 8.2.7.4. Market size, by end-use, 2013 – 2024 8.3. Europe 8.3.1. Market size, by country, 2013 – 2024 8.3.2. Market size, by products, 2013 – 2024 8.3.3. Market size, by type, 2013 – 2024 8.3.4. Market size, by applications, 2013 – 2024 8.3.5. Market size, by end-use, 2013 – 2024 8.3.6. Germany 8.3.6.1. Market size, by products, 2013 – 2024 8.3.6.2. Market size, by type, 2013 – 2024 8.3.6.3. Market size, by applications, 2013 – 2024 8.3.6.4. Market size, by end-use, 2013 – 2024 8.3.7. UK 8.3.7.1. Market size, by products, 2013 – 2024 8.3.7.2. Market size, by type, 2013 – 2024 8.3.7.3. Market size, by applications, 2013 – 2024 8.3.7.4. Market size, by end-use, 2013 – 2024 8.3.8. France 8.3.8.1. Market size, by products, 2013 – 2024 8.3.8.2. Market size, by type, 2013 – 2024 8.3.8.3. Market size, by applications, 2013 – 2024 8.3.8.4. Market size, by end-use, 2013 – 2024 8.3.9. Spain 8.3.9.1. Market size, by products, 2013 – 2024 8.3.9.2. Market size, by type, 2013 – 2024 8.3.9.3. Market size, by applications, 2013 – 2024 8.3.9.4. Market size, by end-use, 2013 – 2024 8.3.10. Italy 8.3.10.1. Market size, by products, 2013 – 2024 8.3.10.2. Market size, by type, 2013 – 2024 8.3.10.3. Market size, by applications, 2013 – 2024 8.3.10.4. Market size, by end-use, 2013 – 2024 8.4. Asia Pacific 8.4.1. Market size, by country, 2013 – 2024 8.4.2. Market size, by products, 2013 – 2024 8.4.3. Market size, by type, 2013 – 2024 8.4.4. Market size, by applications, 2013 – 2024 8.4.5. Market size, by end-use, 2013 – 2024 8.4.6. India 8.4.6.1. Market size, by products, 2013 – 2024 8.4.6.2. Market size, by type, 2013 – 2024 8.4.6.3. Market size, by applications, 2013 – 2024 8.4.6.4. Market size, by end-use, 2013 – 2024 8.4.7. China 8.4.7.1. Market size, by products, 2013 – 2024 8.4.7.2. Market size, by type, 2013 – 2024 8.4.7.3. Market size, by applications, 2013 – 2024 8.4.7.4. Market size, by end-use, 2013 – 2024 8.4.8. Japan 8.4.8.1. Market size, by products, 2013 – 2024 8.4.8.2. Market size, by type, 2013 – 2024 8.4.8.3. Market size, by applications, 2013 – 2024 8.4.8.4. Market size, by end-use, 2013 – 2024 8.4.9. Australia 8.4.9.1. Market size, by products, 2013 – 2024 8.4.9.2. Market size, by type, 2013 – 2024 8.4.9.3. Market size, by applications, 2013 – 2024 8.4.9.4. Market size, by end-use, 2013 – 2024 8.5. Latin America 8.5.1. Market size, by country, 2013 – 2024 8.5.2. Market size, by products, 2013 – 2024 8.5.3. Market size, by type, 2013 – 2024 8.5.4. Market size, by applications, 2013 – 2024 8.5.5. Market size, by end-use, 2013 – 2024 8.5.6. Argentina 8.5.6.1. Market size, by products, 2013 – 2024 8.5.6.2. Market size, by type, 2013 – 2024 8.5.6.3. Market size, by applications, 2013 – 2024 8.5.6.4. Market size, by end-use, 2013 – 2024 8.5.7. Brazil 8.5.7.1. Market size, by products, 2013 – 2024 8.5.7.2. Market size, by type, 2013 – 2024 8.5.7.3. Market size, by applications, 2013 – 2024 8.5.7.4. Market size, by end-use, 2013 – 2024 8.5.8. Mexico 8.5.8.1. Market size, by products, 2013 – 2024 8.5.8.2. Market size, by type, 2013 – 2024 8.5.8.3. Market size, by applications, 2013 – 2024 8.5.8.4. Market size, by end-use, 2013 – 2024 8.6. Middle East and Africa 8.6.1. Market size, by country, 2013 – 2024 8.6.2. Market size, by products, 2013 – 2024 8.6.3. Market size, by type, 2013 – 2024 8.6.4. Market size, by applications, 2013 – 2024 8.6.5. Market size, by end-use, 2013 – 2024 8.6.6. South Africa 8.6.6.1. Market size, by products, 2013 – 2024 8.6.6.2. Market size, by type, 2013 – 2024 8.6.6.3. Market size, by applications, 2013 – 2024 8.6.6.4. Market size, by end-use, 2013 – 2024 8.6.7. Saudi Arabia 8.6.7.1. Market size, by products, 2013 – 2024 8.6.7.2. Market size, by type, 2013 – 2024 8.6.7.3. Market size, by applications, 2013 – 2024 8.6.7.4. Market size, by end-use, 2013 – 2024 Chapter 9 Consolidations 9.1. Mergers and Acquisitions 9.2. Partnership, Joint Ventures and Strategic Alliances/Sales Agreements 9.3. Patent Analysis 9.4. Key players 9.4.1. F Hoffmann-La Roche AG 9.4.1.1. Company overview 9.4.1.2. Key financials 9.4.1.3. Product landscape 9.4.1.4. Strategic initiatives 9.4.1.5. SWOT analysis 9.4.2. Thermo Fisher Scientific Inc. 9.4.2.1. Company overview 9.4.2.2. Key financials 9.4.2.3. Product landscape 9.4.2.4. Strategic initiatives 9.4.2.5. SWOT analysis 9.4.3. Agilent Technologies 9.4.3.1. Company overview 9.4.3.2. Key financials 9.4.3.3. Product landscape 9.4.3.4. Strategic initiatives 9.4.3.5. SWOT analysis 9.4.4. Sigma-Aldrich 9.4.4.1. Company overview 9.4.4.2. Key financials 9.4.4.3. Product landscape 9.4.4.4. Strategic initiatives 9.4.4.5. SWOT analysis 9.4.5. Affymetrix, Inc. 9.4.5.1. Company overview 9.4.5.2. Key financials 9.4.5.3. Product landscape 9.4.5.4. Strategic initiatives 9.4.5.5. SWOT analysis 9.4.6. QIAGEN 9.4.6.1. Company overview 9.4.6.2. Key financials 9.4.6.3. Product landscape 9.4.6.4. Strategic initiatives 9.4.6.5. SWOT analysis 9.4.7. Takara Bio Inc. 9.4.7.1. Company overview 9.4.7.2. Key financials 9.4.7.3. Product landscape 9.4.7.4. Strategic initiatives 9.4.7.5. SWOT analysis 9.4.8. Bio-Rad Laboratories 9.4.8.1. Company overview 9.4.8.2. Key financials 9.4.8.3. Product landscape 9.4.8.4. Strategic initiatives 9.4.8.5. SWOT analysis 9.4.9. Promega Corporation 9.4.9.1. Company overview 9.4.9.2. Key financials 9.4.9.3. Product landscape 9.4.9.4. Strategic initiatives 9.4.9.5. SWOT analysis 9.4.10. New England Biolabs 9.4.10.1. Company overview 9.4.10.2. Key financials 9.4.10.3. Product landscape 9.4.10.4. Strategic initiatives 9.4.10.5. SWOT analysis 9.4.11. VWR International 9.4.11.1. Company overview 9.4.11.2. Key financials 9.4.11.3. Product landscape 9.4.11.4. Strategic initiatives 9.4.11.5. SWOT analysis 9.4.12. Affymetrix, Inc. 9.4.12.1. Company overview 9.4.12.2. Key financials 9.4.12.3. Product landscape 9.4.12.4. Strategic initiatives 9.4.12.5. SWOT analysis 9.4.13. Sequenom Inc. 9.4.13.1. Company overview 9.4.13.2. Key financials 9.4.13.3. Product landscape 9.4.13.4. Strategic initiatives 9.4.13.5. SWOT analysis 9.4.14. 23andMe 9.4.14.1. Company overview 9.4.14.2. Key financials 9.4.14.3. Product landscape 9.4.14.4. Strategic initiatives 9.4.14.5. SWOT analysis 9.4.15. Bayer Diagnostics 9.4.15.1. Company overview 9.4.15.2. Key financials 9.4.15.3. Product landscape 9.4.15.4. Strategic initiatives 9.4.15.5. SWOT analysis 9.4.16. Biocartis 9.4.16.1. Company overview 9.4.16.2. Key financials 9.4.16.3. Product landscape 9.4.16.4. Strategic initiatives 9.4.16.5. SWOT analysis 9.4.17. BioHelix 9.4.17.1. Company overview 9.4.17.2. Key financials 9.4.17.3. Product landscape 9.4.17.4. Strategic initiatives 9.4.17.5. SWOT analysis 9.4.18. BioMerieux 9.4.18.1. Company overview 9.4.18.2. Key financials 9.4.18.3. Product landscape 9.4.18.4. Strategic initiatives 9.4.18.5. SWOT analysis 9.4.19. BGI 9.4.19.1. Company overview 9.4.19.2. Key financials 9.4.19.3. Product landscape 9.4.19.4. Strategic initiatives 9.4.19.5. SWOT analysis 9.4.20. Counsyl 9.4.20.1. Company overview 9.4.20.2. Key financials 9.4.20.3. Product landscape 9.4.20.4. Strategic initiatives 9.4.20.5. SWOT analysis 9.4.21. deCODEme 9.4.21.1. Company overview 9.4.21.2. Key financials 9.4.21.3. Product landscape 9.4.21.4. Strategic initiatives 9.4.21.5. SWOT analysis 9.4.22. Genentech 9.4.22.1. Company overview 9.4.22.2. Key financials 9.4.22.3. Product landscape 9.4.22.4. Strategic initiatives 9.4.22.5. SWOT analysis 9.4.23. Genomictree 9.4.23.1. Company overview 9.4.23.2. Key financials 9.4.23.3. Product landscape 9.4.23.4. Strategic initiatives 9.4.23.5. SWOT analysis 9.4.24. IntegraGen 9.4.24.1. Company overview 9.4.24.2. Key financials 9.4.24.3. Product landscape 9.4.24.4. Strategic initiatives 9.4.24.5. SWOT analysis 9.4.25. LabCorp Diagnostic 9.4.25.1. Company overview 9.4.25.2. Key financials 9.4.25.3. Product landscape 9.4.25.4. Strategic initiatives 9.4.25.5. SWOT analysis

Inquiry Before Buying

Request Sample

About This Report

Report ID10962
Category Healthcare
Publisher Name
No of Pages
Total Views
Published Date
Contact Us